Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fetal retinal pigment epithelium (fRPE) is a cell therapy involving the transplantation of RPE cells derived from human fetal tissue into the subretinal space. The therapy is designed to replace dysfunctional or lost native RPE cells in patients with retinal degenerative diseases like dry age-related macular degeneration (AMD). By restoring the RPE layer, the treatment aims to provide metabolic support to photoreceptors, phagocytose shed outer segments, and maintain the blood-retinal barrier, ultimately preserving vision and preventing further disease progression. The use of fetal-derived cells is based on their high proliferative capacity and potential for integration compared to adult primary cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fetal retinal pigment epithelium.